P. Barrufet

发表

A Simplification Trial Switching From Nucleoside Reverse Transcriptase Inhibitors to Once-Daily Fixed-Dose Abacavir/Lamivudine or Tenofovir/Emtricitabine in HIV-1-Infected Patients With Virological Suppression

D. Podzamczer, B. Clotet, J. Miro, 2009, Journal of acquired immune deficiency syndromes.

Sporadic and epidemic community legionellosis: two faces of the same illness

M. García-nuñez, M. Pedro-Botet, M. Sabrià, 2006, European Respiratory Journal.

Efficacy and safety of direct antiviral agents in a cohort of cirrhotic HCV/HIV-coinfected patients

J. Mallolas, M. Laguno, J. Navarro, 2017, The Journal of antimicrobial chemotherapy.

Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study

D. Podzamczer, E. Ribera, S. Moreno, 2016, PloS one.

Assessing adequacy and risk of drugs in treatments for imprecise clinical diagnoses

Jordi Vitrià, L. Godo, S. Sandri, 2004 .

Decreased Mortality among Patients with Catheter-Related Bloodstream Infections at Catalan Hospitals (2010-2019).

M. Vaqué, A. Hornero, E. Calbo, 2022, The Journal of hospital infection.

Improvement of mitochondrial toxicity in patients receiving a nucleoside reverse-transcriptase inhibitor-sparing strategy: results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA).

Ò. Miró, B. Clotet, E. Negredo, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Genotypic resistance in HIV-infected naive patients receiving abacavir plus lamivudine and efavirenz.

D. Podzamczer, J. Gatell, J. Niubó, 2007, Journal of acquired immune deficiency syndromes.

A multi-agent system approach for monitoring the prescription of restricted use antibiotics

Jordi Sabater-Mir, Josep Puyol-Gruart, Vicenç Torra, 2003, Artif. Intell. Medicine.

Sociodemographic, clinical, and immunological factors associated with SARS-CoV-2 diagnosis and severe COVID-19 outcomes in people living with HIV: a retrospective cohort study

Miguel Ángel Martínez, D. Podzamczer, J. Mallolas, 2021, The Lancet HIV.

A Randomized Clinical Trial Comparing Nelfinavir Or Nevirapine Associated to Zidovudine/Lamivudine in HIV-Infected Naive Patients (The Combine Study)

D. Podzamczer, X. Badia, J. Miro, 2001, Antiviral therapy.

Raltegravir plus abacavir/lamivudine in virologically suppressed HIV-1-infected patients: 48-week results of the KIRAL study

J. Troya, P. Ryan, R. Montejano, 2018, PloS one.

Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)

B. Clotet, M. Odriozola, J. Olalla, 2017, The Journal of antimicrobial chemotherapy.

Prevalence of transmitted antiretroviral resistance and distribution of HIV-1 subtypes among patients with recent infection in Catalonia (Spain) between 2003 and 2005.

C. Tural, T. Pumarola, J. Miro, 2011, Enfermedades infecciosas y microbiologia clinica.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Strategies to reengage patients lost to follow up in HIV care in high income countries, a scoping review

D. Podzamczer, J. Miro, D. Giralt, 2021, BMC Public Health.

Identification of recent HIV-1 infection among newly diagnosed cases in Catalonia, Spain (2006-08).

C. Tural, T. Pumarola, J. Miro, 2012, European journal of public health.

Safe Reduction in CD4 Cell Count Monitoring in Stable, Virally Suppressed Patients With HIV Infection or HIV/Hepatitis C Virus Coinfection.

D. Podzamczer, B. Clotet, J. Romeu, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Primary resistance to integrase strand transfer inhibitors in Spain using ultrasensitive HIV-1 genotyping.

R. Paredes, D. Podzamczer, M. Noguera-Julián, 2020, The Journal of antimicrobial chemotherapy.

How much fat loss is needed for lipoatrophy to become clinically evident?

D. Podzamczer, E. Martinez, E. Ribera, 2009, AIDS research and human retroviruses.

Less Lipoatrophy and Better Lipid Profile With Abacavir as Compared to Stavudine: 96-Week Results of a Randomized Study

D. Podzamczer, J. Gatell, J. Niubó, 2007, Journal of acquired immune deficiency syndromes.

Poor response to hepatitis C virus (HCV) therapy in HIV- and HCV-coinfected patients is not due to lower adherence to treatment.

B. Clotet, G. Sirera, C. Tural, 2006, AIDS research and human retroviruses.

Mortality among methicillin-resistant Staphylococcus aureus carriers in long-term care facilities.

E. Palomera, E. Vendrell, M. Serra-Prat, 2015, Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia.

Correction: Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study

D. Podzamczer, E. Ribera, S. Moreno, 2017, PloS one.

D. Podzamczer, X. Badia, J. Gatell, 2004, HIV clinical trials.

Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DU

D. Podzamczer, B. Clotet, E. Negredo, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: results of the neurocognitive substudy of the SALT randomized clinical trial

J. De La Torre, J. Prada, S. Reus, 2018, The Journal of antimicrobial chemotherapy.

Long-term benefits of nevirapine-containing regimens: multicenter study with 506 patients, followed-up a median of 9 years.

D. Podzamczer, J. Mallolas, M. Leal, 2012, Current HIV research.

Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological Conditions

M. Hernán, A. Winston, C. Sabin, 2017, Journal of acquired immune deficiency syndromes.

Clinical progression of severely immunosuppressed HIV-infected patients depends on virological and immunological improvement irrespective of baseline status.

D. Podzamczer, C. Tural, J. Miro, 2015, The Journal of antimicrobial chemotherapy.

Induction therapy with trizivir plus efavirenz or lopinavir/ritonavir followed by trizivir alone in naive HIV-1-infected adults

J. Gatell, J. Mallolas, F. Vidal, 2008, AIDS.

Genotypic tropism testing of proviral DNA to guide maraviroc initiation in aviraemic subjects: 48‐week analysis of results from the PROTEST study

R. Paredes, D. Podzamczer, E. Poveda, 2017, HIV medicine.